IceCure Medical Ltd (ICCM) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$0.15
Price Target
—
Target Range
— — —
Analyst Rating
—
Forward P/E—
Trailing P/E-0.6x
Forward PEG—
Implied Growth—
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
ICCM Price Target Analysis
Updated June 4, 2026As of June 4, 2026, IceCure Medical Ltd (ICCM) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $10M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, ICCM trades at a trailing P/E of -0.6x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+59.1%
Avg Forward P/E18.3x
Peers with Coverage9 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NVCRNovoCure Limited | $1.8B | $16.15 | $33.50 | +107.4% | Buy | — | 15 |
 XTNTXtant Medical Holdings, Inc. | $65M | $0.46 | — | — | — | — | — |
 ATECAlphatec Holdings, Inc. | $1.2B | $7.68 | $19.71 | +156.6% | Buy | 24.6x | 18 |
 HALOHalozyme Therapeutics, Inc. | $8.3B | $69.82 | $75.00 | +7.4% | Buy | 8.6x | 27 |
 ISRGIntuitive Surgical, Inc. | $144.7B | $407.29 | $607.00 | +49.0% | Buy | 39.2x | 55 |
 BSXBoston Scientific Corporation | $70.9B | $47.69 | $87.37 | +83.2% | Buy | 14.1x | 44 |
 MDTMedtronic plc | $100.1B | $77.95 | $107.25 | +37.6% | Buy | 14.1x | 49 |
 ABTAbbott Laboratories | $151.3B | $87.02 | $127.46 | +46.5% | Buy | 15.9x | 41 |
 SYKStryker Corporation | $113.0B | $295.00 | $385.83 | +30.8% | Buy | 19.7x | 50 |
 ZBHZimmer Biomet Holdings, Inc. | $16.6B | $84.98 | $96.33 | +13.4% | Hold | 10.0x | 42 |
Upside Potential Comparison
ATECNVCRBSXISRGABTMDTSYKZBHWhat if you invested $1,000 in ICCM 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ICCM be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ICCM Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationICCM vs DBVT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs DBV Technologies S.A..
Compare NowICCM — Frequently Asked Questions
Quick answers to the most common questions about buying ICCM stock.
What is the ICCM stock price target for 2026?
The consensus price target for ICCM is $N/A, close to the current price of $0.1517 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
Is ICCM a buy, sell, or hold?
ICCM has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is ICCM stock overvalued or undervalued?
ICCM's current price is $0.1517 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can ICCM stock go?
The most bullish Wall Street analyst has a price target of $N/A for ICCM, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ICCM stock?
ICCM is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ICCM stock forecast?
The 12-month ICCM stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
Should I buy ICCM stock?
ICCM appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ICCM price targets vary so much?
ICCM analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.